ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences
Rhea-AI Summary
ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to LIfT BioSciences. This grant will support the clinical manufacturing of LIfT's Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, a promising allogeneic innate cell therapy.
The N-LIfT platform produces Immunomodulatory Alpha Neutrophils (IMANs), enhanced neutrophils designed to overcome treatment resistance in solid tumors. IMANs can identify and kill solid tumors irrespective of antigen, both directly and indirectly by recruiting the patient's own cancer-killing immune cells.
LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for late-stage clinical trials and beyond. The G-Rex Grant Program is a $20M initiative to advance cell and gene-modified cell therapy development and manufacturing.
Positive
- LIfT BioSciences awarded $300,000 G-Rex® Grant for clinical manufacturing
- N-LIfT platform shows promise in treating solid tumors
- Collaboration with ScaleReady to establish scalable manufacturing process
- Access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners
Negative
- None.
News Market Reaction – TECH
In the trading session that priced this news, TECH gained 0.71%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Award will support clinical manufacturing of the Company's promising Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform
John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex, said: "We're eager to use our expertise to quickly create a highly efficient and scalable G-Rex manufacturing platform that will allow LIfT Biosciences to assess the potential of N-LIfT to penetrate the solid tumor microenvironment, kill cancer cells, and simultaneously recruit the patient's endogenous immune system."
Andrew Willis, Chief Development and Regulatory Officer at LIfT Biosciences, said: "Once infused, N-LIfT produces a new type of myeloid cell called an Immunomodulatory Alpha Neutrophil (IMAN) which is an enhanced neutrophil that is designed to overcome treatment resistance in solid tumours. IMANs can identify solid tumors irrespective of antigen and kill them both directly and indirectly via recruiting the patient's own cancer killing immune cells into the tumour site. We've selected G-Rex as our clinical manufacturing platform and associated expertise that comes with it to expedite our path to patient treatment."
As part of the G-Rex Grant, LIfT will collaborate with ScaleReady to establish a fully closed and semi-automated G-Rex manufacturing process suitable for scale out to late stage clinicals and beyond.
ScaleReady's G-Rex Grant Program is a
About LIfT BioSciences
LIfT Biosciences is a
The company is preparing initiatives with a range of pharmaceutical license partners to develop a portfolio of engineered CAR IMAN cell therapies to destroy a range of solid tumours. See www.LIfTbiosciences.com
Contact: ICR Consilium
Lindsey Neville, Namrata Taak
liftbiosciences@consilium-comms.com
About ScaleReady
ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-lift-biosciences-302271064.html
SOURCE Bio-Techne Corporation